ImmunoCellular Therapeutics (IMUC) Reports Q4 Loss of $1.23/Share
Tweet
Share
E-mailGet Alerts IMUC Hot Sheet
Join SI Premium – FREE
ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($1.23), versus ($7.89) reported last year.
For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VNET Group (VNET) Misses Q2 EPS by 164c
- RBC Capital Reiterates Outperform Rating on Lyft (LYFT), a post-earnings debrief with CFO
- Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
